Dr. Amer Zeidam is an Associate Professor of Medicine (Hematology) at Yale Cancer Center. He completed a hematology/oncology fellowship and a clinical research fellowship in myelodysplastic syndromes (MDS) at Johns Hopkins University where he also earned a Master of Health Science (MHS) degree in Clinical Investigation. He received his MBBS degree from the Faculty of Medicine, University of Jordan, Amman, Jordan before completing his internal medicine residency at Rochester General Hospital, Rochester, NY. Dr. Zeidan specializes in the management of MDS and acute myeloid leukemia (AML). He is a nationally and internationally recognized expert in the clinical management of myeloid malignancies. Dr. Zeidan is the principal investigator on several investigator-initiated, cooperative group and industry-sponsored clinical trials in MDS, AML and other hematologic malignancies. He focuses on the use of immunotherapy, especially combination-based approaches for myeloid malignancies.
Dr. Zeidan has received numerous awards as a blood cancer researcher. He has authored more than 150 peer-reviewed publications and book chapters, most of which as first or senior author including more than 60 original research papers. Dr. Zeidan also serves on the editorial board of important hematology journals such as Blood Reviews and Leukemia and Lymphoma and has been an ad hoc reviewer for many prestigious journals including New England Journal of Medicine, Lancet Oncology, Blood, Journal of Clinical Oncology, JAMA Oncology and many others.